Neuester, zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum
Übersicht
... 8 9 10 11 1 2 3 4 ...

DYADIC startet

Beiträge: 257
Zugriffe: 25.601 / Heute: 5
Dyadic Int. 5,01 $ -1,57% Perf. seit Threadbeginn:   +456,67%
 
DYADIC startet buran
buran:

DYADIC startet

2
04.01.12 19:59
#1
es darf geordert werden,Kurs günstig
231 Beiträge ausgeblendet.
Seite: Übersicht ... 8 9 10 11 1 2 3 4 ...


DYADIC startet buran
buran:

JUPITER, Fla., June

 
21.07.14 19:46
Dyadic Appoints Michael Tarnok, Chairman Of Keryx And Former Pfizer Senior Vice President, To Board Of Directors
15:20 12.06.14

PR Newswire

JUPITER, Fla., June 12, 2014

JUPITER, Fla., June 12, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins, announced today the appointment of Michael Tarnok to the company's Board of Directors.  Mr. Tarnok will also serve on the company's audit and compensation committees.

Logo - photos.prnewswire.com/prnh/20110621/CL06708LOGO

Mr. Tarnok has extensive experience in the pharmaceutical industry across many key areas including finance, operations and marketing. He is the current Chairman and former Interim CEO of Keryx Biopharmaceuticals, Inc., a biotechnology company focused on the development of therapeutics for renal disease. Prior to joining Keryx in 2007, Mr. Tarnok spent the majority of his career at Pfizer Inc., joining in 1989 as Director of Finance for U.S. Manufacturing.  From 2000-2007, he served as Senior Vice President in Pfizer's U.S. Pharmaceuticals Division.  Prior to joining Pfizer, he worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation, and Olivetti Corporation of America.  Mr. Tarnok earned an MBA in marketing from New York University and a Bachelors of Science in accounting from St. John's University.  He also serves on the Board of the Global Health Counsel, a Washington, D.C.-based NGO.

Mark Emalfarb, Chairman and Chief Executive Officer of Dyadic said, "We are excited for Michael to join the Dyadic board while we continue to execute on our plans to leverage the C1 technology platform, grow our enzyme business and become a fully reporting SEC company.  Having led Keryx, a company with a market capitalization over $1 billion, Mr. Tarnok has a proven track record as a forward thinking and accomplished leader. As Dyadic further ventures into new pharmaceutical applications, Mike's wealth of knowledge in drug development, manufacturing, marketing and finance will be invaluable."

Mr. Tarnok added, "I am impressed with the breadth, scope and number of Dyadic's business opportunities in the company's pipeline. The C1 technology platform is already being applied across multiple markets to develop and manufacture enzymes and other proteins to help feed, fuel and heal the world. Dyadic's licensees and collaborators, such as BASF and Abengoa, are global leaders in the industrial enzyme and biofuel markets. The C1 technology also has the potential to breakthrough as a disruptive manufacturing system for large molecule drugs such as vaccines, monoclonal antibodies and other therapeutic proteins. I look forward to sharing my knowledge and experience with the Dyadic team as they continue to execute on their strategic plans for growth."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic's ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic's research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel and (6) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Annual Report filed with the OTC Markets Group on March 31, 2014.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire
DYADIC startet buran
buran:

Dyadic Added to Biofuel Digest Index of

 
21.07.14 19:47
Bioeconomy Stocks
22:15 16.06.14

PR Newswire

JUPITER, Fla., June 16, 2014

JUPITER, Fla., June 16, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins, announced today that Biofuels Digest has selected Dyadic to be included in its Biofuel Digest Index as part of the annual rebalancing of publicly traded stocks included in the index.

Logo - photos.prnewswire.com/prnh/20110621/CL06708LOGO

Danai Brooks, Chief Operating Officer of Dyadic, noted, "Dyadic has gained significant momentum as a critical technology component in the biofuel and bio-based chemical economy.  Earlier this year, Biofuel Digest named Dyadic in the 50 Hottest Companies in Bioenergy.  Abengoa Bioenergy, a Dyadic technology licensee, is opening a first-of-its-kind cellulosic 25 million gallon biofuel plant in Hugoton, Kansas in early July.  We believe that our class-leading enzyme technology and on-site licensing model are the right mix to be successful in this industry."

Biofuel Digest is the world's most widely read biofuel daily covering bioenergy production, finance, policy and research. The Biofuel Digest Index has tracked the bioeconomy since August 2007. Stocks are weighted to reflect market cap, and the extent to which diversified industrial companies are focused on a bio-based strategy.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic's ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic's research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel and (6) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Annual Report filed with the OTC Markets Group on March 31, 2014.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire
DYADIC startet buran
buran:

JUPITER, Fla., July 9, 2014

 
21.07.14 19:48
Dyadic International Announces Participation In Bakenzyme Project
22:20 09.07.14

PR Newswire

JUPITER, Fla., July 9, 2014

JUPITER, Fla., July 9, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today details regarding its new Bakenzyme project. In collaboration with several industry partners, the Bakenzyme project seeks to develop a novel, pure and widely applicable xylanase-oxidase enzyme product for the baking industry.

Logo - photos.prnewswire.com/prnh/20110621/CL06708LOGO

Dyadic's Chief Operating Officer, Danai Brooks, stated, "The aim of this project is to create an enzyme product that improves the structure of bread and increases the bioavailability of health components naturally present in flour. Baking enzymes are a large and growing market. We expect the global baking enzyme market to approach $700 million in five years and believe there is a distinct need for dedicated enzyme mixtures without the negative side activities of products currently available to bakeries."

Enzymes are widely used today by industrial bakeries to increase the stability and rising power of dough, improve crumb structure, increase volume and prevent staling. International bans on the widely popular and highly effective chemical oxidizing agent potassium bromate created the need for safe, yet effective, alternatives. However, most existing enzyme products, such as the currently used glucose oxidase (GOX), are less effective and contain side activities, which can negatively impact bread quality.

Dr. Sandra Hinz, Dyadic's Head of New Product Development, stated, "The novel enzyme mixtures we are developing within the Bakenzyme project will allow manufacturers to combine the benefits of multiple enzymes, improve overall performance and eliminate unwanted side effects without the need for additional additives. As a result consumers can expect consistently higher quality bread with improved texture and more sustainable ingredients. Dyadic's participation in this important program highlights the capabilities of our C1 Expression System to develop innovative products.  Participation in the Bakenzyme project and other private-public programs helps us advance our technology platform and increase the breadth of our enzyme library, which may have applications in a wide variety of industries."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce.  For further information, please visit Dyadic's website at www.dyadic.com.  Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.

Cautionary Note Regarding for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements within the meaning of the federal securities laws. Statements about our beliefs and expectations regarding our technology platform, research efforts, the need for dedicated enzyme mixtures, consumer experience and our successful production of enzymes with minimal negative side activities may constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements to reflect actual results, any changes in expectations or any change in events.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire
DYADIC startet buran
buran:

9350 glatt durchen Ami Ticker RT

 
21.07.14 19:49
DYADIC startet buran
buran:

thread update

 
21.07.14 19:50
RTK 1,57 $ RTP +1,29 Pott +74,44% ,GrB
Der ARIVA.DE Newsletter
Bleiben Sie informiert mit dem
wöchentlichen Marktüberblick
von ARIVA.DE!
E-Mail-Adresse
Ich möchte Benachrichtigungen von ARIVA.DE erhalten.
Ja, ich habe die Datenschutzhinweise gelesen und akzeptiert (Pflichtfeld).
DYADIC startet buran
buran:

Reports-Q2-2014-Financial-Results

 
17.08.14 19:39
DYADIC startet buran
buran:

guck Dir mal die Turbine an hier Du:::::

 
17.08.14 19:40
::::::::::::::::::: 1,85 $ +8,82% +0,15 $
In Euro: 1,3806 € | Nasdaq OTC Other, 15.08.14::::::: wowwwwww ..::hopshops
DYADIC startet buran
buran:

jo und dann sinnma denn auch schon hier:

 
17.08.14 19:41
SK 1,85 $ SKP +8,82 Pott +105,56% ,GrB
DYADIC startet buran
buran:

Files-Form-10-Registration-Statement

 
18.08.14 16:27
DYADIC startet buran
buran:

DYAI 18-08

 
19.08.14 11:57
Datum Erster Hoch Tief Schluss     Stücke Volumen
  18.08.14      1,87      1,87§1,75 1,75 $ 113.675 205 T

GrB
DYADIC startet buran
buran:

Dynamische Absicherung

 
19.12.14 17:58
Eine Absicherung, bei der die Kauf- oder Verkaufslimits jeweils dynamisch an den jeweiligen Kurs angepasst werden, nennt man dynamische Absicherung. Beispielsweise könnte man mit einer solchen Absicherung einen Stopp-Kurs von 5% unter dem aktuellen Kurs festlegen. http://www.ariva.de/extras/lexikon.m?begriff=Dynamische_Absicherung
DYADIC startet buran
buran:

09er Tickersatz

 
10.01.15 20:12
Datum Erster Hoch Tief Schluss     Stücke Volumen
  09.01.15      0,94    0,9799§0,94 0,9799 $ 7.123 6.782

GrB
DYADIC startet buran
buran:

21.435 hamma unter'm Ticker Hammer ON AIR

 
16.01.15 21:54
DYADIC startet buran
buran:

28.500 Echtzeit GEBONGT

 
20.07.15 21:32
DYADIC startet buran
buran:

die Laterne scheint::::

 
30.08.15 15:13
:::::::::::::::::::: 0,98 $ +2,08% +0,02 $
In Euro: 0,8762 € | Nasdaq OTC Other, 28.08.15 ,GrB
DYADIC startet buran
buran:

Büchse Grün:::

 
06.05.16 14:45
::::::::: 1,71 $ +0,59% +0,01 $
In Euro: 1,498 € | 05.05.16 Nasdaq OTC Other ,GrB
DYADIC startet buran
buran:

Hübschdrück:::

 
09.07.16 14:11
DYADIC startet buran
buran:

StockNewsNow.com Publishes New

 
29.12.16 03:35
SNNLive Video Interviews with Dyadic International, Inc. Team Discussing Dyadic's C1 Technology Platform and the Biologics Industry
Mittwoch, 16.11.2016 14:30 von PR Newswire  http://www.ariva.de/news/...new-snnlive-video-interviews-with-5950074
DYADIC startet buran
buran:

Herzblatthubschrauber:::

 
05.07.17 01:31
:::::::::::::::::::: 1,38 $ +0,73% +0,01 $
In Euro: 1,2154 € | 03.07.17 Nasdaq OTC Other ,GrB
DYADIC startet buran
buran:

JUPITER, FL .......... ::

 
04.10.17 18:49
– August 16, 2017 (GLOBE NEWSWIRE) – Dyadic International, Inc. (OTCQX: DYAI) (“Dyadic”) announced that its Board of Directors has authorized a new stock repurchase program, under which the Company may repurchase up to $5 million of its outstanding common stock. www.dyadic.com/investors/media-center/press-releases/

DYADIC startet Biotechboy

News

 
Dyadic International Inc (NASDAQ:DYAI) on Thursday reported a 119% increase in first-quarter research and development revenue compared to the same period a year ago.

The Jupiter, Florida-based company said it saw a net loss of $2.2 million, or $0.08 per share, compared to a net loss of $2.0 million, or $0.07 per share, for the same period a year ago.

www.proactiveinvestors.com/companies/news/...enue-220008.html

Seite: Übersicht ... 8 9 10 11 1 2 3 4 ...

Hot-Stocks-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem Dyadic International Forum

  
Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
2 256 DYADIC startet buran Biotechboy 13.05.19 12:43
  1 DYADIC INTL INC. DL-,001 SuperTenere berlin25m 13.03.09 10:12

--button_text--